Table 2. Adjusted Hazard Ratios (HRs) and 95% Confidence Intervals (CIs) for Site-Specific Cancers, by Proportion of Follow-Up Days Covered (PDC) With Statins,^a Israel, 1998-2006.

Site	Cases, n	PDC Quintiles	Adjusted for Age and Sex		Fully Adjustedb
			HR (95% CI)	P Value	HR (95% CI)	P Value
All-site	8,662	1	1 [Reference]		1 [Reference]
		2	1.03 (0.96–1.10)	.38	0.86 (0.80–0.93)	.001
		3	0.93 (0.87–0.99)	.001	0.75 (0.70–0.81)	.001
		4	0.82 (0.77–0.86)	.001	0.73 (0.68–0.79)	.001
		5	0.81 (0.76–0.86)	.001	0.90 (0.84–0.96)	.002
Colorectal	1,247	1	1 [Reference]		1 [Reference]
		2	0.92 (0.76–1.11)	.41	0.89 (0.74–1.08)	.26
		3	0.80 (0.66–0.96)	.02	0.78 (0.65–0.94)	.01
		4	0.73 (0.61–0.89)	.001	0.73 (0.60–0.87)	.001
		5	0.93 (0.78–1.10)	.41	0.93 (0.78–1.11)	.43
Breast	1,368	1	1 [Reference]		1 [Reference]
		2	0.86 (0.73–1.02)	.09	0.84 (0.71–0.99)	.03
		3	0.76 (0.64–0.90)	.002	0.73 (0.61–0.87)	.001
		4	0.81 (0.68–0.96)	.02	0.77 (0.65–0.92)	.005
		5	1.10 (0.93–1.29)	.27	1.03 (0.87–1.22)	.10
Prostate	1,311	1	1 [Reference]		1 [Reference]
		2	0.89 (0.73–1.07)	.22	0.81 (0.67–0.99)	.04
		3	0.76 (0.63–0.92)	.005	0.72 (0.59–0.87)	.001
		4	0.82 (0.68–0.99)	.04	0.75 (0.62–0.89)	.002
		5	0.98 (0.84–1.16)	.86	0.95 (0.81–1.13)	.57
Lung and bronchus	584	1	1 [Reference]		1 [Reference]
		2	0.82 (0.62–1.08)	.17	0.81 (0.61–1.06)	.14
		3	0.86 (0.66–1.13)	.30	0.85 (0.65–1.12)	.24
		4	0.72 (0.54–0.96)	.02	0.71 (0.53–0.94)	.02
		5	1.01 (0.79–1.29)	.93	0.97 (0.76–1.25)	.86
Female genital organsc	427	1	1 [Reference]		1 [Reference]
		2	1.01 (0.75–1.37)	.93	0.89 (0.66–1.22)	.50
		3	0.97 (0.72–1.32)	.88	0.85 (0.63–1.16)	.33
		4	0.74 (0.53–1.03)	.07	0.65 (0.46–0.91)	.01
		5	0.88 (0.69-1.13)	.44	0.78 (0.57–1.06)	.12
Hematopoieticd	681	1	1 [Reference]		1 [Reference]
		2	0.88 (0.69–1.13)	.32	0.87 (0.68–1.12)	.29
		3	0.74 (0.58–0.94)	.02	0.72 (0.56–0.92)	.01
		4	0.69 (0.54–0.89)	.004	0.65 (0.51–0.85)	.001
		5	0.76 (0.61–0.96)	.02	0.69 (0.55–0.88)	.002
Leukemia	177	1	1 [Reference]		1 [Reference]
		2	0.72 (0.45–1.14)	.16	0.72 (0.45–1.15)	.17
		3	0.58 (0.37–0.94)	.03	0.58 (0.36–0.91)	.03
		4	0.55 (0.34–0.89)	.02	0.54 (0.33–0.88)	.01
		5	0.63 (0.61–0.96)	.03	0.58 (0.37–0.91)	.02
Lymphoma	429	1	1 [Reference]		1 [Reference]e
		2	0.91 (0.67–1.24)	.55	0.87 (0.64–1.20)	.42
		3	0.87 (0.64–1.18)	.37	0.82 (0.61–1.11)	.21
		4	0.78 (0.57–1.07)	.14	0.72 (0.52–0.99)	.05
		5	0.78 (0.58–1.04)	.10	0.69 (0.51–0.94)	.002

^a Calculated by dividing the quantity of statin packs dispensed, from date of first statin dispensation, by the total follow-up time. Data are presented as percentages unless otherwise indicated.

^b Adjusted for age, sex, marital status, area of residence, nationality, socioeconomic level, years of stay in Israel, obesity, diabetes mellitus, hypertension, cardiovascular disease, efficacy, hospitalizations and visits to physicians a year before first statin dispensation, as well as for asthma, and chronic obstructive pulmonary disease (for lung and bronchus cancers).

^c Including uterus, ovary, cervix, fallopian tube, vagina, and vulva.

^d Leukemia, lymphoma, and multiple myeloma.

^e P for trend < .002.